Talking with (and Listening to) Your Patients About Marijuana Use...What Every Psychiatrist Should Know

Saturday May 6, 2017
8:00 AM - 1:00 PM
Swedish Medical Center - Cherry Hill Campus, James Tower Educational Conference Center

This training is jointly-provided by the American Psychiatric Association and Washington State Psychiatric Association.  

Pre-registration is closed. Walk-ins are welcome.

Overview/Description
This program will focus on what psychiatrists need to know about marijuana use, including the mechanism of action of marijuana, its pharmacokinetics and pharmacodynamics, its beneficial and adverse effects, its effects in patients with psychiatric conditions and other medical conditions, the legal status of marijuana, and how psychiatrists can discuss marijuana use with their patients.

Schedule
7:00 - Registration, Breakfast & Exhibits
8:00 - Introduction
8:10 - History of cannabis in medicine, and the history of legal restrictions on its popular usage and in medical research
8:30 - The endocannabinoid system, CB1 & CB2 receptors, endogenous cannabinoids, & distribution
8:55 - Routes of administration, bioavailability, distribution & elimination, and actions of the various cannabinoids; FDA approved cannabinoids
9:30 - Break & Exhibits
9:40 - Clinical research on usefulness in psychiatry: anxiety, depression, psychosis, PTSD, sleep, violence Break
9:55 - Clinical research on usefulness in non-psychiatric medicine: inflammation, pain, spasm, appetite, nausea, HIV, epilepsy, and other conditions
10:15 - Hazards in cannabis use: addiction, accidents, psychosis, cognitive and motor deficits, withdrawal, cardio-respiratory, other psychiatric symptoms
10:40 - Current legal restrictions and limitations on cannabis "recommendation" by psychiatric practitioners
10:50 - Taking a history relevant to medical cannabis use
11:15 - How to talk with and listen to your patients who are interested In or actively using cannabis for medical reasons, or who are using it recreationally while in treatment for psychiatric disorder.
11:45 - Cumulative Q & A

Learning Objectives

  • Discuss the CNS activity of cannabis, and the physiologic actions of cannabis and the cannabinoid system; 
  • Discuss the medical usefulness and hazards of cannabis, particularly pertaining to psychiatric disorders; 
  • Discuss the medico-legal climate regarding cannabis and legal restrictions on the medical use of cannabis; 
  • Take a relevant history from, listen to, educate and counsel patients who wish to use or are using cannabis for medical treatment, or who are using it recreationally while in psychiatric treatment

Speaker
Henry, Levine, MD, Private Practice

Pricing
WSPA Members: $100.00
Non-Members: $125.00
Nurses/Non-Physicians: $75.00
UW Psychiatry Residents (ID required at registration): Free

CME
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Psychiatric Association (APA) and WA State Psychiatric Association. The APA is accredited by the ACCME to provide continuing medical education for physicians.

The APA designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Platinum Sponsor

 

 

 

 

Gold Sponsors
         

Exhibitors